Javelin
AI-Assisted Chemoproteomics Platform
Accelerating & de-risking drug discovery with comprehensive proteome-wide drug target profiling
Why It Matters
Fast, reliable on-target validation and early off-target profiling determine discovery success
Target discovery is the initial and most uncertain step in drug development. Traditional drug R&D takes more than 10 years and over $2 billion from discovery to launch.
Drug discovery needs a standardized, efficient, matrix-relevant way to confirm target engagement and surface safety risks early—but currently, there is none.
Toxicity and side effects can be caused by off-target interactions, making comprehensive profiling essential for de-risking development programs.
- Traditional R&D: >10 years, >$2B investment
- Target discovery: Most uncertain development step
- Off-target interactions cause toxicity/side effects
- No standardized validation method exists
- Need: Matrix-relevant, efficient profiling
What Javelin Delivers
Proteome-wide peptide/domain-level interaction maps with drug dose-responses, ready in 4-6 weeks
- On-target confirmation: Validates predicted binding
- Binding-site clues: Peptide/domain-level resolution
- Off-target list: Enables go/no-go decisions
- Modality-agnostic: Small molecules, degraders, ADCs, biologics
- Matrix-flexible: Cells, organoids, tissues
- Dose-response curves: Quantitative binding data
Why Javelin Wins
Massive trypsinization method with AI outperforms conventional approaches
- Higher resolution: Superior to CETSA/TPP, DARTS, SPROX, classic LiP-MS
- Simpler workflow: Fewer conditions than full melting/denaturant series
- AI integration: Closes "predict ↔ measure" loop
- Increased sensitivity: Massive trypsinization vs. limited proteolysis
- Better accuracy: AI-based quantification reduces errors
Javelin's massive trypsinization approach dramatically simplifies sample preparation while increasing sensitivity to target detection.
Combined with SynapSpec, our next-generation DIA analysis platform, Javelin delivers unmatched precision through advanced spectral deconvolution and AI-based quantification.
This enables accelerated AI-based drug discovery by providing experimental validation to close the prediction loop.
Technology Deep Dive
Massive Trypsinization
Revolutionary sample preparation technique that outperforms limited proteolysis
- Simplified: Single trypsin treatment in native conditions
- Efficient: Filtered to remove irrelevant peptides
- Sensitive: Dramatically increased target detection
- Accurate: Improved quantification vs. two-step methods
- Fast: Streamlined workflow reduces time to results
SynapSpec
Cutting-edge proteomics technology platform that accelerates drug discovery through deep learning optimization and real-time mass spectrometry analysis
- Deep learning-optimized workflows
- Real-time data processing and analysis
- Automated mass spectrometry optimization
- Cross-platform compatibility
Case Studies & Interactive Data
Explore real experimental data and interactive visualizations from validated target profiling studies, featuring comprehensive QC metrics, dose-response curves, and structural mapping results
Explore Interactive Data →Transform Your Discovery Program
Get decision-ready target profiling with binding site resolution in just 4-6 weeks